Catalog No.
DHF39901
Description
Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolysaccharide-associated protein 3, Leukocyte-derived seven transmembrane domain receptor
Concentration
1.59 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P61073
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-936564, MDX-1338, MDX1338，CAS: 1375830-34-4
Clone ID
Ulocuplumab
Management of Waldenström macroglobulinemia in 2020, PMID: 33275726
What is new in the treatment of Waldenstrom macroglobulinemia?, PMID: 31591468
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions, PMID: 32758634
Immunotherapy for small-cell lung cancer: emerging evidence, PMID: 26882955
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway, PMID: 26646452
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma, PMID: 31672767
Selected Articles from This Issue, PMID: 31941683
At the Bedside: Profiling and treating patients with CXCR4-expressing cancers, PMID: 33089889
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation, PMID: 26190113
Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia, PMID: 34289017
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia, PMID: 32135579
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies, PMID: 23213054
CXCR4 as a therapeutic target in acute myeloid leukemia., PMID:39261603
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies., PMID:39096094
Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)., PMID:38475811
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia., PMID:35339405
The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies., PMID:35183534
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia., PMID:34289017
Management of Waldenström macroglobulinemia in 2020., PMID:33275726
At the Bedside: Profiling and treating patients with CXCR4-expressing cancers., PMID:33089889
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions., PMID:32758634
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia., PMID:32135579
Selected Articles from This Issue., PMID:31941683
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma., PMID:31672767
What is new in the treatment of Waldenstrom macroglobulinemia?, PMID:31591468
Immunotherapy for small-cell lung cancer: emerging evidence., PMID:26882955
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway., PMID:26646452
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation., PMID:26190113
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies., PMID:23213054
For research use only. Not for human or drug use.
